FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 820 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR New on NCI’s Websites for March 2023 March 24, 2023 Latest episode of our podcast for cancer researchers March 23, 2022 Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in... November 21, 2020 ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July June 25, 2025 Load more HOT NEWS Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma Young Adult Cancer Awareness Week: Recognizing Adolescent and Young Adults Cancer... SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... EMA Recommends Granting a Marketing Authorisation for Ivosidenib
